1. Search Result
Search Result
Isoforms Recommended: Akt1 Akt1
Results for "

AKT1

" in MedChemExpress (MCE) Product Catalog:

98

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

9

Natural
Products

4

Recombinant Proteins

17

Antibodies

1

Click Chemistry

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-146459

    Akt Cancer
    Akt1-IN-1 (compound 5b) is a potent and selective Akt1 inhibitor with an IC50 value of 18.79 nM in MIA Paca-2 cells. Akt1-IN-1 does not exhibit obvious teratogenicity, hepatotoxicity and cardiotoxicity (No Observed Adverse Effect Level > 100 µM). Akt1-IN-1 can be used for researching anticancer [1].
    Akt1-IN-1
  • HY-RS00542

    Small Interfering RNA (siRNA) Akt Others

    AKT1 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AKT1 Human Pre-designed siRNA Set A
    AKT1 Human Pre-designed siRNA Set A
  • HY-RS00544

    Small Interfering RNA (siRNA) Akt Others

    Akt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Akt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Akt1 Rat Pre-designed siRNA Set A
    Akt1 Rat Pre-designed siRNA Set A
  • HY-RS00543

    Small Interfering RNA (siRNA) Akt Others

    Akt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Akt1 Mouse Pre-designed siRNA Set A
    Akt1 Mouse Pre-designed siRNA Set A
  • HY-173155

    Akt Cancer
    AKT1-IN-9 (4) is a selective mutant AKT1(E17K) inhibitor, with EC50 values of 9 nM and 995 nM in LAPC4-CR and SkBr3 cells, respectively [1].
    AKT1-IN-9
  • HY-161438

    Akt Cancer
    Akt1-IN-3 (Compd 7) is an inhibitor of AKT1. Akt1-IN-3 inhibits AKT1- E17K with IC50 < 15 nM [1].
    Akt1-IN-3
  • HY-163577

    Akt Cancer
    Akt1-IN-5 (Compound 115) is an Akt1 inhibitor (IC50: <15 nM) [1]
    Akt1-IN-5
  • HY-163578

    Akt Cancer
    Akt1-IN-6 (Compound 273) is an Akt1 inhibitor (IC50: <15 nM) [1]
    Akt1-IN-6
  • HY-163579

    Akt Cancer
    Akt1-IN-7 (Compound 370) is an Akt1 inhibitor (IC50: <15 nM) [1].
    Akt1-IN-7
  • HY-173122

    Akt Cancer
    Akt1-IN-8 (Compound JL18) is a potent and oral bioavailable (41%) inhibitor of AKT1 kinase, with an IC50 of 8.8 nM. Akt1-IN-8 exhibits significant antiproliferative effects against PC-3 prostate cancer cells, with an IC50 of 3.0 μM. Akt1-IN-8 can reduce phosphorylated GSK3β levels [1].
    Akt1-IN-8
  • HY-161439

    Akt Cancer
    Akt1-IN-4 (Compound 62) is an AKT1-E17K inhibitor with an IC50 value of less than 15 nM [1].
    Akt1-IN-4
  • HY-148868A

    Akt CDK Cancer
    Akt1&PKA-IN-2 ((R)-29) is an inhibitor of PKB/AKT with cyclin-dependent kinase 2 (CDK2) selectivity. Akt1&PKA-IN-2 inhibits AKT1, PKAa and CDK2 a with IC50 values of 0.007 µM, 0.01 µM and 0.69 µM, respectively [1].
    Akt1&PKA-IN-2
  • HY-129119

    Akt Caspase Cancer
    Akt1/Akt2-IN-2 (compound 7) is an allosteric dual Akt1 and Akt2 inhibitor (IC50=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells [1].
    Akt1/Akt2-IN-2
  • HY-50862
    Akt1/Akt2-IN-1
    1 Publications Verification

    Akt Cancer
    Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of Akt1 (IC50=3.5 nM) and Akt2 (IC50=42 nM), with potent and balanced activity [1].
    Akt1/Akt2-IN-1
  • HY-148868

    Akt PKA CDK Others
    Akt1&PKA-IN-1 is a potent dual Akt/PKA inhibitor with IC50 values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) [1].
    Akt1&PKA-IN-1
  • HY-16032

    Akt Cancer
    AKT-I-1 is a selective inhibitor of Akt1, with an IC50 of 4.6 µM [1].
    Akt1-IN-2
  • HY-RS00545

    Small Interfering RNA (siRNA) Others

    AKT1S1 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT1S1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    AKT1S1 Human Pre-designed siRNA Set A
    AKT1S1 Human Pre-designed siRNA Set A
  • HY-176299

    Akt Cancer
    Tanerasertib (Compound 456) is an AKT1 inhibitor with an IC50 of less than 15 nM against AKT1 E17K. Tanerasertib can be used in the study of cancer [1].
    Tanerasertib
  • HY-154960

    Akt Apoptosis Microtubule/Tubulin Cancer
    Tubulin/AKT1-IN-1 (Compound D1-1) is an inhibitor of tubulin polymerization and AKT pathway activation. Tubulin/AKT1-IN-1 significantly inhibits the proliferation and metastasis of H1975 cells and slightly induced their apoptosis and can be used for non-small-cell lung cancer (NSCLC) research [1].
    Tubulin/AKT1-IN-1
  • HY-169960

    mTOR Cancer
    2DII is a potent and selective mTORC2 inhibitor. 2DII selectively binds mSin1 PH domain and decreases the expression of AKT1 phosphorylation [1].
    2DII
  • HY-19982
    AKT-IN-6
    1 Publications Verification

    Akt Cancer
    AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1).
    AKT-IN-6
  • HY-W750451

    Akt Cancer
    Reptoside, an iridoid glucoside, is a DNA damaging active agent. Reptoside has strong interactions with Trp352 and Tyr335 in AKT1 [1].
    Reptoside
  • HY-19719A
    Miransertib hydrochloride
    10+ Cited Publications

    ARQ-092 hydrochloride

    Akt Parasite Infection Cancer
    Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research [1]. Miransertib hydrochloride is effective against Leishmania .
    Miransertib hydrochloride
  • HY-19719
    Miransertib
    10+ Cited Publications

    ARQ-092

    Akt Parasite Infection Cancer
    Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research [1]. Miransertib is effective against Leishmania .
    Miransertib
  • HY-143611

    Akt Cancer
    AKT-IN-8 is a potent AKT inhibitor with IC50s of 4.46, 2.44, and 9.47 nM for AKT1, AKT2, and AKT3, respectively [1].
    AKT-IN-8
  • HY-153640

    Akt Cancer
    AKT-IN-14 (Example 2) is a potent AKTinhibitor with the IC50 values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 can be used in cancer research [1].
    AKT-IN-14
  • HY-153640A

    Akt Cancer
    AKT-IN-14 (Example 2) free baseis a potent AKTinhibitor with the IC50 values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 free basecan be used in cancer research [1].
    AKT-IN-14 free base
  • HY-137458A

    ARQ 751 trihydrochloride

    Akt Cancer
    Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer [1].
    Vevorisertib trihydrochloride
  • HY-100018
    BAY1125976
    1 Publications Verification

    Akt Cancer
    BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.
    BAY1125976
  • HY-123390

    Bcr-Abl Akt Cancer
    DB07107 is a potent agent resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent Akt1 inhibitor with an IC50 value of 360 nM [1] .
    DB07107
  • HY-W013816

    AMPK Akt Metabolic Disease
    Dipentyl phthalate is an endocrine-disrupting phthalate plasticizer. Dipentyl phthalate increases AMPK phosphorylation and decreases AKT1 phosphorylation and SIRT1 levels. Dipentyl phthalate reduces adrenocorticotropic hormone levels. Dipentyl phthalate is a testicular toxicant [1].
    Dipentyl phthalate
  • HY-13254A
    A-674563 hydrochloride
    5 Publications Verification

    Akt Cancer
    A-674563 hydrochloride is a potent and selective Akt1 inhibitor with Ki of 11 nM.
    A-674563 hydrochloride
  • HY-13254
    A-674563
    5 Publications Verification

    Akt Cancer
    A-674563 is an orally active Akt1 inhibitor with a Ki of 11 nM.
    A-674563
  • HY-16666
    3CAI
    4 Publications Verification

    Akt Cancer
    3CAI is a potent and specific AKT1 and AKT2 inhibitor.
    3CAI
  • HY-145281

    PROTACs Akt Cancer
    MS98 is a potent and selective PROTAC AKT degrader. MS98 depletes cellular total AKT (T-AKT) with the DC50 value of 78 nM. MS98 binds to AKT1, AKT2, and AKT3 with Kds of 4 nM, 140 nM, and 8.1 nM, respectively [1].
    MS98
  • HY-145282
    MS170
    1 Publications Verification

    PROTACs Akt Cancer
    MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total AKT (T-AKT) with the DC50 value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with Kds of 1.3 nM, 77 nM, and 6.5 nM, respectively [1].
    MS170
  • HY-162285

    Akt Cancer
    Anticancer agent 189 (compound 4) is an anticancer agent that antagonizes CRC effects by targeting AKT1 [1].
    Anticancer agent 189
  • HY-112148

    Akt Cancer
    AKT-IN-2 is a potent, selective and orally bioavailable AKT inhibitor with an IC50 of 5 nM for AKT1 [1].
    AKT-IN-2
  • HY-W013816R

    AMPK Akt Reference Standards Metabolic Disease
    Dipentyl phthalate (Standard) is the analytical standard of Dipentyl phthalate. This product is intended for research and analytical applications. Dipentyl phthalate is an endocrine-disrupting phthalate plasticizer. Dipentyl phthalate increases AMPK phosphorylation and decreases AKT1 phosphorylation and SIRT1 levels. Dipentyl phthalate reduces adrenocorticotropic hormone levels. Dipentyl phthalate is a testicular toxicant [1].
    Dipentyl phthalate (Standard)
  • HY-138767

    Akt Cancer
    AKT-IN-5 (Example 8) is a Akt inhibitor with IC50 values of 450 nM and 400 nM for Akt1 and Akt2, respectively [1].
    AKT-IN-5
  • HY-15431
    Capivasertib
    65+ Cited Publications

    AZD5363

    Akt Autophagy Cancer
    Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.
    Capivasertib
  • HY-15965
    Uprosertib
    15+ Cited Publications

    GSK2141795

    Akt Cancer
    Uprosertib (GSK2141795) is a potent and selective pan-Akt inhibitor with IC50 values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.
    Uprosertib
  • HY-15965A

    GSK2141795 hydrochloride

    Akt Cancer
    Uprosertib hydrochloride (GSK2141795 hydrochloride) is a potent and selective pan-Akt inhibitor with IC50 values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.
    Uprosertib hydrochloride
  • HY-18271
    CaMKII-IN-1
    5 Publications Verification

    CaMK Autophagy Inflammation/Immunology
    CaMKII-IN-1 is a potent and highly selective CaMKII inhibitor with IC50 of 63 nM; significantly high selectivity against CaMKIV, MLCK, p38a, Akt1, and PKC.
    CaMKII-IN-1
  • HY-151613

    PROTACs Akt Cancer
    MS15 is a potent and selective AKT PROTAC degrader. MS15 inhibits the AKT1, -2, and -3 activities, with IC50 values of 798 nM, 90 nM, and 544 nM, respectively [1].
    MS15
  • HY-10425
    Rizavasertib
    10+ Cited Publications

    A-443654

    Akt Cancer
    A-443654 is a pan-Akt inhibitor and has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM) [1].
    Rizavasertib
  • HY-151613A

    PROTACs Akt Cancer
    MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC50 values of 798 nM, 90 nM, and 544 nM, respectively [1].
    MS15 TFA
  • HY-15186A
    Ipatasertib dihydrochloride
    45+ Cited Publications

    GDC-0068 dihydrochloride; RG-7440 dihydrochloride

    Organoid Akt Cancer
    Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.
    Ipatasertib dihydrochloride
  • HY-15727
    Afuresertib
    10+ Cited Publications

    GSK2110183; LAE002

    Akt PKC ROCK Cancer
    Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively [1] .
    Afuresertib
  • HY-15727A
    Afuresertib hydrochloride
    10+ Cited Publications

    GSK2110183 hydrochloride; LAE002 hydrochloride

    Akt PKC ROCK Cancer
    Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively [1] .
    Afuresertib hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: